EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CRVS: Corvus Pharma Com

12 Nov 25 15:59
LAST:

8.190

CHANGE:
 0.02		OPEN:
8.190		HIGH:
8.305		ASK:
10.150		VOLUME:
326.3K
CHG(%):
0.24		PREV:
8.170		LOW:
8.030		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Nov 258.1908.3058.0308.190326.3K
11 Nov 257.9208.2707.7758.1701.05M
10 Nov 257.7408.1507.4807.9101.26M
07 Nov 257.6907.7807.0107.600946.6K
06 Nov 257.6008.0507.4107.8201.65M
05 Nov 257.5407.9607.1307.5301.57M
04 Nov 257.4007.6607.3307.6401.21M
03 Nov 257.8907.9907.5207.6801.04M
31 Oct 257.7608.4407.5008.0401.89M
30 Oct 257.6808.0507.6007.7601.33M

COMPANY PROFILE

Name:Corvus Pharma Com
About:Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.corvuspharma.com
CUSIP:221015100
CIK:0001626971
ISIN:US2210151005
FIGI:BBG009F0TGH8
LEI:549300I3AVJ8F75NCX65

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-7.53 
Forward P/E:-16.75 
PEG Ratio:-0.18 
Price to Book:7.47 
Return on Assets:-0.29 
Return on Equity:-0.69 
EPS Ratio:-1.10 
EBITDA:5.91M 
Shares:74.51M 
Market Cap:610.27M 

TECHNICAL INDICATORS

MA5:7.943.2%
MA10:7.834.5%
MA20:7.637.4%
MA50:6.9917.2%
MA100:5.7941.5%
MA200:4.8768.3%
STO9:72.53
STO14:77.06
RSI14:67.00 
MTM14:0.84
ROC14:0.11 
ATR:0.56 
Week High:8.311.4%
Week Low:7.0116.8%
Month High:8.443.1%
Month Low:6.8168.3%
Year High:10.0022.1%
Year Low:2.54222.4%
Volatility:45.46